RCUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Arcus Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$22.14+0.02 (+0.09%)
Close on Oct 19, 2026
- Market cap
- $2.79B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$5.67 (+34.43%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Arcus Biosciences, Inc. saw revenue fall 55.3% to $117.00M over the twelve months to Jun 30, 2026. Free cash flow was -$475.00M.
Revenue
$117.00M
-55.3% vs. a year earlier
Operating income
-$486.00M
TTM Q2 2026
Free cash flow
-$475.00M
TTM Q2 2026
EPS, diluted
-$3.90
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.79B
- P/E ratio
- –
- Price to sales
- 23.86
- Price to book
- 6.02
- Dividend yield
- –
- Free cash flow yield
- -17.01%
Fundamentals
- Revenue
- $117.00M
- Net income
- -$460.00M
- EPS, diluted
- -$3.90
- Free cash flow
- -$475.00M
- Book value per share
- $3.68
- Diluted shares
- 126M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
$117.00M-55.3% YoY
Operating income
-$486.00M
Net income
-$460.00M
EPS, diluted
-$3.90
Free cash flow
-$475.00M
Reported periodTrailing twelve months